MRS Meetings and Events

 

SB01.04.08 2024 MRS Spring Meeting

Versatile Application of Nanoscale Metal-Organic Frameworks for Intratumoral Delivery

When and Where

Apr 24, 2024
11:15am - 11:30am

Room 428, Level 4, Summit

Presenter

Co-Author(s)

Eunseo Choi1,Conroy Sun1

Oregon State University1

Abstract

Eunseo Choi1,Conroy Sun1

Oregon State University1
Recent preclinical and clinical studies have highlighted the improved outcomes of combination radiotherapy and immunotherapy. Concurrently, the development of high atomic number (high-Z) metallic nanoparticles as radiation dose enhancers has been explored to widen the therapeutic window of radiotherapy and potentially enhance immune activation. Due to their high X-ray attenuation and high density, metal-based nanoparticles also have the potential to serve as imaging agents. Exploiting high-Z metal nanoparticles would provide clinical advantages for image-guided radiotherapy for targeted cancer treatment.<br/>Despite the numerous advances in the field of drug delivery, there are still unmet needs that could lead to the development of a therapeutic molecule delivery carrier. In this study, we seek intraturmoral delivery of metal-organic frameworks to induce a robust stimulation of anticancer immunity for a systemic and long-lasting therapeutic benefit. By utilizing hafnium and iron-based metal-organic frameworks, we target immune cells with other targeted cancer therapies for synergistic advantages. We employ this nanomaterial as a pharmaceutical carrier system for the delivery of a wide range of materials, from small molecules to macromolecules. Radiotherapy-induced local tissue damage and inflammation have the potential to generate tumor antigen and release danger-associated molecular patterns. Nanoscale metal-organic frameworks are a versatile platform for combination radiotherapy. In addition to serving as drug carriers, our high-Z metal-organic frameworks are attractive nanomaterials that serve as contrast agents in biomedical imaging. We conducted phantom studies <i>in vitro</i> and <i>in vivo</i>, using microCT for real-time monitoring, which will facilitate advanced analysis of tumor cells and their responses to therapy. Intratumoral immunotherapy provides the capacity to manipulate the tumor microenvironment by targeting cells within the tumor microenvironment, making it an attractive therapeutic approach.

Keywords

biomaterial | Hf | nanostructure

Symposium Organizers

Weibo Cai, University of Wisconsin--Madison
Bella Manshian, KU Leuven
Dalong Ni, Shanghai Jiao Tong University.
Ruirui Qiao, The University of Queensland

Symposium Support

Bronze
EXODUS BIO
JINAN NANOMEDICINE (HONG KONG) CO., LIMITED
Journal of Nanobiotechnology
KeAi-Bioactive Materials
POP Biotechnologies
Portrai Inc.
Promega Corporation
RAYSOLUTION Healthcare Co., Ltd
Shandong Madic Technology Co., Ltd.
United Well Technologies (China) Limited

Publishing Alliance

MRS publishes with Springer Nature